Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: A case report and review of the literature

Journal of Medical Case Reports

Volumn 5, Issue , 2011, Pages

  Krishnadas, Rajeev ^a   Krishnadas, Ranjit ^b   Cavanagh, Jonathan ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESCITALOPRAM; METHOTREXATE; RISPERIDONE; SALAZOSULFAPYRIDINE; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN;

ADULT; ANEMIA; ANGINA PECTORIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HUMAN; INDIAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 79953124783     PISSN: 17521947     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-5-112     Document Type: Article

References (22)

1. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. D Symmons G Turner R Webb P Asten E Barrett M Lunt D Scott A Silman, Rheumatology (Oxford) 2002 41 793 800 10.1093/rheumatology/41. 7.793 12096230 (Pubitemid 34822963)
2. Prevalence of rheumatoid arthritis in the adult Indian population. AN Malaviya SK Kapoor RR Singh A Kumar I Pande, Rheumatol Int 1993 13 131 134 10.1007/BF00301258 8310203 (Pubitemid 24018727)
3. Management of rheumatoid arthritis: summary of NICE guidance. C Deighton R O'Mahony J Tosh C Turner M Rudolf, BMJ 2009 338 702 10.1136/bmj.b702 19289413
4. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. C Dickens L McGowan D Clark-Carter F Creed, Psychosom Med 2002 64 52 60 11818586 (Pubitemid 34137399)
5. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. DC Ang H Choi K Kroenke F Wolfe, J Rheumatol 2005 32 1013 1019 15940760 (Pubitemid 40828071)
6. DAS 28 for defining remission in rheumatoid arthritis in Indian patients. R Aneja R Grover S Shankar V Dhir R Gupta A Kumar, Indian J Rheumatol 2006 1 48 52 10.1016/S0973-3698(10)60003-9
7. Clinical outcomes following a trial of sertraline in rheumatoid arthritis. JR Slaughter JC Parker MP Martens KL Smarr JE Hewett, Psychosomatics 2002 43 36 41 10.1176/appi.psy.43.1.36 11927756 (Pubitemid 34214160)
8. Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report. BT Baune H Eyre, J Med Case Rep 2010 4 6 10.1186/1752-1947-4-6
9. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. CB Zhu RD Blakely WA Hewlett, Neuropsychopharmacology 2006 31 2121 2131 16452991 (Pubitemid 44413189)
10. Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study. J Cavanagh C Paterson J McLean S Pimlott M McDonald J Patterson D Wyper I McInnes, Ann Rheum Dis 2010 69 1251 1252 10.1136/ard.2009.107912 20371552
11. The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. M Maes, Neuro Endocrinol Lett 2008 29 287 291 18580840
12. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. N Muller MJ Schwarz S Dehning A Douhe A Cerovecki B Goldstein-Muller I Spellmann G Hetzel K Maino N Kleindienst HJ Moller V Arolt M Riedel, Mol Psychiatry 2006 11 680 684 10.1038/sj.mp.4001805 16491133 (Pubitemid 43989814)
13. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. S Tyring A Gottlieb K Papp K Gordon C Leonardi A Wang D Lalla M Woolley A Jahreis R Zitnik D Cella R Krishnan, Lancet 2006 367 29 35 10.1016/S0140-6736(05)67763-X 16399150 (Pubitemid 43038667)
14. Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs. ZQ Zhao S Chiechio YG Sun KH Zhang CS Zhao M Scott RL Johnson ES Deneris KJ Renner RWt Gereau ZF Chen, J Neurosci 2007 27 6045 6053 10.1523/JNEUROSCI.1623-07.2007 17537976 (Pubitemid 46849764)
15. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. RH Dworkin AB O'Connor J Audette R Baron GK Gourlay ML Haanpaa JL Kent EJ Krane AA Lebel RM Levy SC Mackey J Mayer C Miaskowsk SN Raja AS Rice KE Schmader B Stacey S Stanos RD Treede DC Turk GA Walco CD Wells, Mayo Clin Proc 2010 85 3 S14 10.4065/mcp.2009.0649 20194146
16. Antidepressant therapy and C-reactive protein levels. SM O'Brien LV Scott TG Dinan, Br J Psychiatry 2006 188 449 452 16648531
17. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. P Vollmar S Nessler SR Kalluri HP Hartung B Hemmer, Int J Neuropsychopharmacol 2009 12 525 536 10.1017/S1461145708009425 18922202
18. Pro-inflammatory biomakers in depression: treatment with venlafaxine. JE Piletz A Halaris O Iqbal D Hoppensteadt J Fareed H Zhu J Sinacore CL Devane, World J Biol Psychiatry 2009 10 313 323 10.3109/15622970802573246 19921973
19. Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit Toll-like receptors. S Sacre M Medghalchi B Gregory F Brennan R Williams, Arthritis Rheum 2010 62 683 693 10.1002/art.27304 20131240
20. Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. B Yu J Becnel M Zerfaoui R Rohatgi AH Boulares CD Nichols, J Pharmacol Exp Ther 2008 327 316 323 10.1124/jpet.108.143461 18708586
21. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. JH Meyer S Kapur B Eisfeld GM Brown S Houle J DaSilva AA Wilson S Rafi-Tari HS Mayberg SH Kennedy, Am J Psychiatry 2001 158 78 85 10.1176/appi.ajp.158.1.78 11136637 (Pubitemid 32047250)
22. Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders. A Kling M Danell-Boman H Stenlund R Dahlqvist, Arthritis Rheum 2009 61 1322 1327 10.1002/art.24673 19790123